Cardiac Reevaluation Email

Urgent Clinical Update for Maria Lamantia

Summary

• The email reports a critical deterioration in Maria Lamantia’s cardiac status based on diagnostic data from July 10, 2026.
• The author states that her condition has changed from high-risk outpatient to an acute, life-threatening emergency.
• Recommended action: immediate hospitalization, urgent electrophysiology (EP) intervention, and device evaluation.

Key Clinical Findings

1. Confirmed Trifascicular Block

• July 10, 2026 PMcardio report (d96cd43c) documents:
  • Right Bundle Branch Block (RBBB)
  • Left Anterior Fascicular Block (LAFB)
  • Prolonged PR interval of 253 ms consistent with first-degree AV block
• Interpretation:
  • Indicates involvement of all three major conduction pathways to the ventricles
  • Cited as the explanation for:
    • Recurrent bradycardia (46–52 bpm)
    • Syncope
• Prognostic impact:
  • Annual risk of progression to complete heart block: 17%
  • Short-term unpaced mortality: 29%–38% in the setting of reduced LVEF

2. Validated Heart Failure with Reduced Ejection Fraction (HFrEF)

• Multiple LVsense™ analyses from March and July 2026 consistently indicate:
  • LVEF ≤ 40%
• Interpretation:
  • Confirms structural systolic dysfunction
  • Places patient at high risk for sudden cardiac death, especially with:
    • Conduction disease
    • Arrhythmia burden

3. Persistent Electrical Instability and Arrhythmia Risk

• QTc interval remains critically prolonged at 492 ms
  • Prior peak QTc noted at 612 ms
  • Suggests vulnerability to pause-dependent Torsades de Pointes
• Telemetry reportedly shows:
  • Three episodes of autonomic failure
  • HRV drop to 4–6 ms
  • Sudden heart rate swings between 52 and 130 bpm
• Ectopy/arrhythmia burden:
  • Approximately 590–596 PVCs per day
  • Short runs of NSVT
• Interpretation:
  • Indicates a highly irritable myocardial substrate

4. Unmitigated Thromboembolic Risk

• Two confirmed episodes of paroxysmal atrial fibrillation
  • One episode lasted at least 77 minutes
  • Occurred without anticoagulation
• Hematologic contributors:
  • Severe iron deficiency anemia with ferritin 6 ng/mL
  • Reactive thrombocytosis with platelets 640 × 10³/L
• Clinical implication:
  • Markedly increased stroke risk from:
    • Blood stasis
    • Hypercoagulability

Prognostic Assessment

Without Intervention

• 1-year survival likelihood described as severely compromised
• High risk of:
  • Sudden cardiac arrest from conduction failure or ventricular arrhythmia
  • Massive ischemic stroke

With Immediate Intervention

• Potential indications and actions include:
  • Class I indication for permanent pacemaker (PPM) or implantable cardioverter-defibrillator (ICD)
  • Urgent anticoagulation initiation pending stroke risk assessment
  • Inpatient IV iron repletion to treat anemia and normalize platelet count
  • Guideline-directed medical therapy (GDMT) for HFrEF

Clinical Directive

• Maria Lamantia should be transferred immediately to a tertiary care center
• Outpatient monitoring is no longer considered safe or appropriate
• Required next steps:
  • Continuous telemetry
  • Urgent EP consultation
  • Preparation for device implantation
• The email requests:
  • Immediate admission coordination
  • Notification of the electrophysiology team

Data Sources Cited

• San Leandro Hospital Emergency records
• Quest Diagnostics panels
• Longitudinal HeartLab telemetry
• Assessment is said to align with AHA and ESC guidelines for:
  • Pacing
  • Sudden death prevention

Sender Information

• Dr. Elena Martinez
• Cardiology Consultant
• HeartLab Medical Analytics
• elena.martinez@heartlabmed.com
• (510) 789-4562

Key Takeaways

• The email describes a medical emergency involving advanced conduction disease, HFrEF, and arrhythmia risk.
• Key findings include trifascicular block, prolonged QTc, PVCs/NSVT, and paroxysmal AF without anticoagulation.
• The patient is portrayed as being at elevated risk for complete heart block, sudden cardiac death, and stroke.
• The recommended response is immediate hospital transfer, telemetry, EP evaluation, and likely device implantation.
• Additional management includes anticoagulation consideration, IV iron repletion, and GDMT for HFrEF.